Guggenheim cuts target for Amgen stock to USD 378.00
Published on 10/13/2026 at 16:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst caution and operating scale
- Guggenheim lowered its Amgen target from USD 388.00 to USD 378.00 on October 12, 2026.
- Amgen reported quarterly revenue of USD 10.05 billion against USD 9.43 billion consensus.
- Amgen stock costs EUR 372.58 at Lang & Schwarz on October 13, 2026 at 4:31 p.m. CEST.
- Amgen had a USD 225.2 billion market capitalization and a 25.94 price-to-earnings ratio as of October 13, 2026.
Guggenheim kept a Neutral rating on Amgen (US0311621009) and lowered its price target from USD 388.00 to USD 378.00 on October 12, 2026, according to GuruFocus. The move puts the latest target below Amgen's Nasdaq quote in US dollars, while the euro quotation at Lang & Schwarz stood at EUR 372.58 on October 13, 2026 at 4:31 p.m. CEST.
Target cut tests valuation
The USD 10.00 reduction equals 2.58 percent of the earlier target, a precise signal that the analyst view has become more cautious even as the rating remains Neutral. GuruFocus also reported a GF Value of USD 368.11 against a share price of USD 417.57 on October 12, 2026, a comparison that places the model value below the market quotation.
For investors, the important distinction is between the analyst target and the company's operating results. The target is a forward assessment, while the latest quarterly figures describe a completed reporting period.
Quarterly revenue reaches USD 10.05 billion
Amgen reported quarterly revenue of USD 10.05 billion, compared with USD 9.43 billion consensus, according to MarketBeat. The USD 620.00 million difference represents 6.58 percent above consensus, giving the operating picture a stronger numerical footing than the revised target alone suggests.
The same quarterly report showed earnings per share of USD 6.29 against a USD 5.62 consensus estimate. Amgen's full-year 2026 earnings guidance was USD 22.30-23.50 per share, while the analyst consensus cited by MarketBeat stood at USD 22.94.
Price and valuation in view
Amgen's Nasdaq quote was USD 417.26 on October 13, 2026 at 10:34 a.m. EDT, according to the finance quote, with a market capitalization of USD 225.2 billion and a price-to-earnings ratio of 25.94. The 52-week range was USD 288.00 to USD 447.03 in the MarketBeat data dated October 10, 2026.
At Lang & Schwarz, Amgen was trading at EUR 372.58 on October 13, 2026 at 4:31 p.m. CEST. The euro quote gives German investors a separate market reference from the Nasdaq quotation and does not convert the US dollar figures used for the target, valuation or quarterly results.
Upcoming reporting date
Amgen's investor-relations page lists an Amgen third-quarter 2026 earnings conference call among its upcoming events and identifies the second-quarter 2026 earnings presentation among its recent materials. The company describes its business as biotechnology research, development and manufacturing focused on medicines for serious illnesses, with operations spanning oncology, inflammation, cardiovascular disease, bone health, neuroscience and rare diseases, according to Amgen.
Market context
Market context: Market report S&P 500.
Trading reference for Amgen
The price at Lang & Schwarz was EUR 372.58 on October 13, 2026 at 4:31 p.m. CEST, while the Nasdaq quotation was USD 417.26 at 10:34 a.m. EDT on the same date. The two figures belong to different currencies and venues, so the analyst target and operating comparisons remain in US dollars.
The further course of trading is shown by the continuously updated real-time quote of Amgen stock.
Amgen stock key data
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 13, 2026 at 4:31 p.m. CEST: EUR 372.58
- Market capitalization: USD 225.2 billion as of October 13, 2026
- 52-week range: USD 288.00-447.03 as of October 10, 2026
- Sector / Industry: Healthcare / biotechnology
- Index membership: S&P 500
